FOSTER CITY (dpa-AFX) – Gilead Sciences, Inc. (GILD) Wednesday said it launched PURPOSE 5, the company’s Phase 2 study to evaluate lenacapavir as long-acting HIV prevention option. Gilead’s PURPOSE studies evaluate the safety and efficacy of lenacapavir for pre-exposure prophylaxis (PrEP), meaning, reduce the chance of getting HIV. PURPOSE 5…Read More
Gilead Launches New Study To Evaluate Lenacapavir In HIV Prevention As Part Of PURPOSE Program
